Literature DB >> 19829301

Melanoma thickness trends in the United States, 1988-2006.

Vincent D Criscione1, Martin A Weinstock.   

Abstract

Over the past two decades, numerous efforts have been initiated to improve screening and early detection of melanoma both in the United States and worldwide. It is commonly believed that these efforts have contributed to the stabilization of melanoma mortality, and that the proportion of thick melanoma with unfavorable prognosis is on the decline. Data obtained from 17 population-based cancer registries of the Surveillance Epidemiology and End Result (SEER) program of the National Cancer Institute for 1988-2006 were used to examine trends in melanoma tumor thickness. For malignant melanoma cases with recorded thickness, the proportionate distribution among four thickness categories (<or=1, 1.01-2, 2.01-4, and >4 mm) remained relatively stable over the 19-year study period, however, for melanomas resulting in death, the proportion of thick tumors increased. The most substantial change occurred in the proportion of melanoma in situ, which nearly doubled from 1988 to 2006. Surveillance and early detection efforts in the United States have not resulted in a substantial reduction in the proportion of tumors with prognostically unfavorable thickness. Continued improvement and new methods of screening, especially among demographics with higher incidence of thick tumors, is necessary.

Entities:  

Mesh:

Year:  2009        PMID: 19829301     DOI: 10.1038/jid.2009.328

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  40 in total

1.  Cutaneous melanoma in situ: translational evidence from a large population-based study.

Authors:  Simone Mocellin; Donato Nitti
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.

Authors:  Sandra L Wong; Charles M Balch; Patricia Hurley; Sanjiv S Agarwala; Timothy J Akhurst; Alistair Cochran; Janice N Cormier; Mark Gorman; Theodore Y Kim; Kelly M McMasters; R Dirk Noyes; Lynn M Schuchter; Matias E Valsecchi; Donald L Weaver; Gary H Lyman
Journal:  J Clin Oncol       Date:  2012-07-09       Impact factor: 44.544

3.  Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study.

Authors:  Erin X Wei; Abrar A Qureshi; Jiali Han; Tricia Y Li; Eunyoung Cho; Jennifer Y Lin; Wen-Qing Li
Journal:  J Am Acad Dermatol       Date:  2016-07-16       Impact factor: 11.527

4.  Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications.

Authors:  Phyllis A Gimotty; Ronald Shore; Nancy L Lozon; Jeanne Whitlock; Sidan He; Fawn D Vigneau; Lois Dickie; David E Elder; Xiaowei Xu; Ann G Schwartz; DuPont Guerry
Journal:  J Invest Dermatol       Date:  2016-06-25       Impact factor: 8.551

5.  Skin biopsy utilization and melanoma incidence among Medicare beneficiaries.

Authors:  M A Weinstock; J P Lott; Q Wang; L J Titus; T Onega; H D Nelson; L Pearson; M Piepkorn; R L Barnhill; J G Elmore; A N A Tosteson
Journal:  Br J Dermatol       Date:  2017-03-01       Impact factor: 9.302

6.  The influence of dermatologist and primary care physician visits on melanoma outcomes among Medicare beneficiaries.

Authors:  Richard G Roetzheim; Ji-Hyun Lee; Jeanne M Ferrante; Eduardo C Gonzalez; Ren Chen; Kate J Fisher; Kymia Love-Jackson; Ellen P McCarthy
Journal:  J Am Board Fam Med       Date:  2013 Nov-Dec       Impact factor: 2.657

7.  The MPATH-Dx reporting schema for melanocytic proliferations and melanoma.

Authors:  Michael W Piepkorn; Raymond L Barnhill; David E Elder; Stevan R Knezevich; Patricia A Carney; Lisa M Reisch; Joann G Elmore
Journal:  J Am Acad Dermatol       Date:  2013-10-28       Impact factor: 11.527

8.  Novice identification of melanoma: not quite as straightforward as the ABCDs.

Authors:  R Benjamin Aldridge; Matteo Zanotto; Lucia Ballerini; Robert B Fisher; Jonathan L Rees
Journal:  Acta Derm Venereol       Date:  2011-03       Impact factor: 4.437

9.  Nano-characterization of two closely related melanoma cell lines with different metastatic potential.

Authors:  Justyna Gostek; Szymon Prauzner-Bechcicki; Benedikt Nimmervoll; Katrin Mayr; Joanna Pabijan; Peter Hinterdorfer; Lilia A Chtcheglova; Małgorzata Lekka
Journal:  Eur Biophys J       Date:  2014-12-04       Impact factor: 1.733

Review 10.  Screening and prevention measures for melanoma: is there a survival advantage?

Authors:  Clara Curiel-Lewandrowski; Suephy C Chen; Susan M Swetter
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.